Baseline PET/CT imaging parameters for prediction of treatment outcome in Hodgkin and diffuse large B cell lymphoma: a systematic review

Autor: Alejandro F. Frangi, Charalampos Tsoumpas, R. Frood, Andrew Scarsbrook, Chirag Patel, C. Burton, Fergus V. Gleeson
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Oncology
medicine.medical_specialty
Treatment outcome
PET-CT
MEDLINE
Pet ct imaging
QUANTIZATION PARAMETERS
030218 nuclear medicine & medical imaging
03 medical and health sciences
INTERNATIONAL PROGNOSTIC INDEX
0302 clinical medicine
Radiomics
Fluorodeoxyglucose F18
Internal medicine
Positron Emission Tomography Computed Tomography
Medicine
Humans
Radiology
Nuclear Medicine and imaging
In patient
HETEROGENEITY
Internal validation
Retrospective Studies
Science & Technology
business.industry
EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY
INTERIM
Radiology
Nuclear Medicine & Medical Imaging
General Medicine
Diffuse large B-cell lymphoma
Outcome prediction
medicine.disease
Prognosis
TOTAL LESION GLYCOLYSIS
F-18-FDG PET/CT
METABOLIC TUMOR VOLUME
Tumor Burden
Treatment Outcome
030220 oncology & carcinogenesis
Positron-Emission Tomography
EXPERIENCE
Lymphoma
Large B-Cell
Diffuse
business
Life Sciences & Biomedicine
Hodgkin lymphoma
PROGRESSION-FREE SURVIVAL
ISSN: 1619-7070
Popis: Purpose To systematically review the literature evaluating clinical utility of imaging metrics derived from baseline fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) for prediction of progression-free (PFS) and overall survival (OS) in patients with classical Hodgkin lymphoma (HL) and diffuse large B cell lymphoma (DLBCL). Methods A search of MEDLINE/PubMed, Web of Science, Cochrane, Scopus and clinicaltrials.gov databases was undertaken for articles evaluating PET/CT imaging metrics as outcome predictors in HL and DLBCL. PRISMA guidelines were followed. Risk of bias was assessed using the Quality in Prognosis Studies (QUIPS) tool. Results Forty-one articles were included (31 DLBCL, 10 HL). Significant predictive ability was reported in 5/20 DLBCL studies assessing SUVmax (PFS: HR 0.13–7.35, OS: HR 0.83–11.23), 17/19 assessing metabolic tumour volume (MTV) (PFS: HR 2.09–11.20, OS: HR 2.40–10.32) and 10/13 assessing total lesion glycolysis (TLG) (PFS: HR 1.078–11.21, OS: HR 2.40–4.82). Significant predictive ability was reported in 1/4 HL studies assessing SUVmax (HR not reported), 6/8 assessing MTV (PFS: HR 1.2–10.71, OS: HR 1.00–13.20) and 2/3 assessing TLG (HR not reported). There are 7/41 studies assessing the use of radiomics (4 DLBCL, 2 HL); 5/41 studies had internal validation and 2/41 included external validation. All studies had overall moderate or high risk of bias. Conclusion Most studies are retrospective, underpowered, heterogenous in their methodology and lack external validation of described models. Further work in protocol harmonisation, automated segmentation techniques and optimum performance cut-off is required to develop robust methodologies amenable for clinical utility.
Databáze: OpenAIRE
Externí odkaz: